你的研究,Your research值得被产业看见。deserves to be seen.

把实验室里的早期成果交给 Tula。几分钟写清楚,AI 评估离概念验证还有多远,Tula 团队为你对接合适的产业方。Bring your early-stage work to Tula. Describe it in minutes, see how far it is from proof of concept, and let the Tula team introduce you to the right industry partners.

很多好的早期研究,停在了论文和实验记录里。不是不够好,而是产业看不懂、找不到、不放心。Tula 把它们写成产业读得懂的语言,并把公开的节奏,交还到你手里。A great deal of good early research stops at the paper and the lab notebook. Not because it isn't good, but because industry can't read it, can't find it, or can't trust it yet. Tula puts it in the language industry reads, and keeps the pace of disclosure in your hands.

让早期成果,更快被看懂。Early work, understood faster.

3分钟min
描述一项成果to describe your work

用平实的话填写机制、阶段、数据与权属,没有专利也可以提交。Mechanism, stage, data and ownership in plain words. No patent required.

2–3个工作日days
拿到完整报告to a full report

初步结论更早返回,先看到离概念验证还有多远。A first read comes back sooner, showing the distance to proof of concept.

4个维度axes
统一评分标准one scoring standard

科学、数据、竞品、可交易性,每一项都附理由。Science, data, landscape and dealability, each with a reason.

一项成果,在 Tula 上的五步。Five steps, from your lab to industry.

01
你来做You约 3 分钟About 3 min

描述你的成果Describe your work

机制、阶段、已有数据和权属,用平实的话写下来。没有专利也可以提交。Mechanism, stage, data and ownership in plain words. No patent required.

机制MechanismGLP-1 / GIP / 胰高血糖素三重激动剂Triple GLP-1 / GIP / glucagon agonist
阶段Stage临床前 · 小鼠药代已完成Preclinical · mouse PK done
权属Rights无专利 · 课题组所有No patent · held by the lab
02
TulaTula2–3 个工作日2–3 days

拿到 AI 就绪度报告Get your AI readiness report

离 POC 还有多远、数据可信度,以及先改哪里。四个维度评分,每项附理由。How far from POC, how credible the data is and what to fix first. Four axes, each with a reason.

  • 科学Science88
  • 数据Data71
  • 竞品Landscape80
  • 可交易性Dealability84
03
TulaTula报告之后After the report

匿名进入管线库Listed anonymously

成果以匿名简介进入管线库,机构名称和课题组信息默认遮住。Your work enters the pipeline as an anonymous brief. Your institution and lab stay hidden.

机构Institution
某大学药学院 · 王教授课题组School of Pharmacy · Prof. Wang's lab
适应症Indication 肥胖Obesity阶段Stage 临床前Preclinical
你批准之前,产业方看不到Hidden from industry until you approve
04
TulaTula按需On demand

Tula 团队线下对接The Tula team introduces you

把匿名简介带给需求相符的药企 BD 与投资方,每一步都先征求你的意见。We take the brief to pharma BD teams and investors who fit, checking with you at every step.

TULA-0105匿名简介Anonymous brief
P药企 BDPharma BD查看中Reviewing有兴趣Interested
I投资方Investor查看中Reviewing有兴趣Interested
C产业合作方Partner查看中Reviewing暂不匹配Not a fit
Tula
药企 BD 想认识你Pharma BD wants an intro对接前先征求你的同意We ask you before anything is shared
同意Approve稍后Later
05
你批准之后After you approve

你点头,才开放Opens only on your yes

每份 CDA 由你批准,数据室逐人授权、带水印并留有日志,条款由你和产业方直接谈。You approve each CDA. The data room is granted per person, watermarked and logged; terms are yours to agree.

允许查看数据室Allow data room access

一份给产业看的简介,一份给你自己看的报告。A brief for industry, and a report for you.

  • 01
    匿名简介Anonymous brief

    产业方最先看到的一页,机构名称默认遮住。The first page industry sees, with your name hidden by default.

  • 02
    就绪度报告Readiness report

    只给你看:四维评分和理由、离 POC 的距离、下一步。Just for you: four scored axes, distance to POC, next steps.

资产简介Asset brief匿名版AnonymousTULA-0105
机制Mechanism
GLP-1 / GIP / 胰高血糖素三重激动剂Triple GLP-1 / GIP / glucagon agonist
适应症Indication
肥胖Obesity
阶段Stage
临床前 · 体外活性与小鼠药代已完成Preclinical · in vitro and mouse PK done
权属Rights
无专利 · 课题组所有No patent · held by the lab
机构Institution
某大学药学院School of Pharmacy
82
Tula 就绪度Tula readiness

离 POC 还差一项动物药效研究One animal efficacy study from POC

就绪度报告Readiness report示例SampleTULA-0105 · 由 Aegis 生物世界模型生成by the Aegis Bio World Model
82
Tula 就绪度Tula readiness

机制有差异化,体外与药代数据扎实。缺一项动物药效研究。A distinct mechanism with solid in vitro and PK data. One animal efficacy study is missing.

科学Science88

三重激动机制,同类少见Triple agonism, few peers

数据Data71

缺体内药效No in vivo efficacy yet

竞品Landscape80

赛道拥挤,但机制有区分度Crowded field, distinct mechanism

可交易性Dealability84

权属清晰,产业关注度高Clear rights, strong industry interest

离 POC 的距离Distance to POC

体外活性In vitro小鼠药代Mouse PK动物药效Animal efficacyPOC

下一步建议Suggested next steps

  1. 在 DIO 小鼠模型上做一项 4 周药效研究Run a 4-week efficacy study in DIO mice
  2. 补充与司美格鲁肽的头对头对照Add a head-to-head arm against semaglutide
  3. 考虑在披露前先提交专利申请Consider filing a patent before wider disclosure
资产与评分均为虚构示例Fictional sample asset and scores四个维度 · 每项附理由Four axes · reasons for each

公开之前,每一步都由你决定。Before anything is shared, every step is yours to decide.

你的成果先以匿名形式出现。是否继续、对谁开放、开放多少,都由你来点头。Your work appears anonymously first. Whether to go further, with whom and how much is always your call.

01

匿名简介An anonymous brief

产业方先看到的只有简介,不含机构名称和课题组信息。Industry sees the brief first, without your institution or lab.

02

你批准才披露Disclosed only with your approval

对方申请进一步了解,由你决定是否同意。签保密协议、公开名称、开放完整数据,每一步都要你点头。When someone asks to learn more, you decide. An NDA, your name, the full data: each step needs your yes.

03

随时撤回Revocable at any time

任何时候都可以撤回已开放的权限。数据室逐人授权、带水印并留有日志。Withdraw access whenever you like. The data room is granted per person, watermarked and logged.

还没准备好上架?先问问 AI。Not ready to list? Ask the AI first.

● 离 POC 还有多远Distance to POC

描述你的成果,看清数据、计划、团队和 IP 上的缺口。Describe your work and see the gaps in data, plan, team and IP.

● 下一步怎么做What to do next

用平实的语言梳理法规、CMC 和试验设计问题。Walk through regulatory, CMC and trial-design questions in plain words.

● 怎么走到交易Towards a deal

思考交易结构,以及产业方会要哪些资料。Think through deal structures and what industry will ask for.

Vinda AI 是一个独立产品,在新标签页打开,Tula 不会把你的上架信息传给它。Vinda AI is a separate product. It opens in a new tab and Tula does not send it your listing details.

agent.aegiss.bio
VINDA AI
对话示例,仅作示意Example conversation, illustrative only

“好的早期研究,不该停在实验室里。我们想让它被产业读懂,也让研究者守住每一步的主动权。”“Good early research shouldn't stop at the lab. We want industry to understand it, and researchers to stay in control of every step.”

Tula团队Team
Tula早期药物资产交易所EARLY-STAGE ASSET EXCHANGE
适合谁Who it is for
  • 高校课题组University labs

    把论文之外的成果,变成产业能评估的东西。Turn work beyond the paper into something industry can assess.

  • 研究所与技术转移办公室Institutes and tech-transfer offices

    用同一份标准整理多个项目。Present many projects to one standard.

  • 早期生物科技团队Early biotech teams

    一份报告讲清管线,少做重复尽调。One report that explains the pipeline.

可选协助Optional help
  • FDA · CMC

    法规路径规划;化学、生产与质量控制。Regulatory path; chemistry, manufacturing and controls.

  • 药理研究Pharmacology

    药理研究支持。Pharmacology study support.

  • 共同投资Co-investment

    好项目逐案协商;收费服务开工前谈定范围和报价。Case by case; paid work is scoped and quoted first.

相关产品Related products

提交之前,你可能想问。Before you submit, you might ask.

没找到答案?在 Telegram 联系我们:Something else? Message us on Telegram: @Lance_xyz

没有专利能提交吗?Can I submit without a patent?

可以。需要的话,Tula 可以协助先行申请。我们也会核查主要地区的专利与抢注风险。Yes. If you want one, Tula can help you file first, and we check key regions for patent and squatting risks.

谁能看到我的成果?Who can see my work?

Tula 团队对接的产业方只会看到匿名简介。机构名称和完整资料,只在你批准、对方签署保密协议之后才开放。Industry contacts introduced by the Tula team see only the anonymous brief. Your name and full materials open after you approve and they sign an NDA.

提交之后会发生什么?What happens after I submit?

你会立刻看到初步判断,通常 2–3 个工作日内收到完整报告。之后由 Tula 团队判断适合对接哪些产业方,并先征求你的意见。You get a first read right away and the full report within 2–3 business days. The Tula team then decides which industry contacts fit, and checks with you first.

要收费吗?Does it cost anything?

提交和就绪度报告没有强制费用。FDA、CMC 等协助服务,会在开工前与你谈定范围和报价。Submitting and the readiness report carry no obligation. Help such as FDA or CMC work is scoped and quoted with you before it starts.

我的团队推不动后续开发怎么办?What if my team can't take it further?

这在高校很常见。常见做法是首付折让、后端以销售分成回收;Tula 也可以承担部分开发,按承担的工作分成。That is common for university labs. A typical deal is a smaller upfront with royalties later; Tula can also take on part of the work and share in proportion.

交易条款由谁来谈?Who negotiates the terms?

由你和产业方直接谈。Tula 不定价,也不替你成交。You and the industry party, directly. Tula does not set the price or close on your behalf.

带一项真实的成果来。Bring a real result.